|

AI-aided Optical Coherence Tomography for the Detection of Basal Cell Carcinoma

RECRUITINGSponsored by Maastricht University Medical Center
Actively Recruiting
SponsorMaastricht University Medical Center
Started2023-04-10
Est. completion2024-12-31
Eligibility
Age18 Years+
View on ClinicalTrials.gov →

NCT05817279

Summary

Basal cell carcinoma (BCC) is the most common form of cancer among the Caucasian population. A BCC diagnosis is commonly establish by means of an invasive punch biopsy (golden standard). Optical coherence tomography (OCT) is a safe non-invasive diagnostic modality which may replace biopsy if an OCT assessor is able to establish a high confidence BCC diagnosis. Hence, for clinical implementation of OCT, diagnostic certainty should be as high as possible. Artificial intelligence in the form of a clinical decision support system (CDSS) may improve the diagnostic certainty of newly trained OCT assessors by highlighting suspicious areas on OCT scans and by providing diagnostic suggestions (classification). This study will evaluate the effect of a CDSS on the diagnostic certainty and accuracy of OCT assessors.

Eligibility

Age: 18 Years+
Inclusion Criteria:

* Patients (18+ years)
* Patient underwent OCT scan and punch biopsy for an equivocal BCC lesion

Exclusion Criteria:

\- Patient unable to sign informed consent

Conditions3

Basal Cell CarcinomaCancerOptical Coherence Tomography

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.